Browse > Article
http://dx.doi.org/10.13160/ricns.2017.10.2.95

3D-QSAR Study on Imidazopyridazines Derivatives as Potent Pim-1 Kinase Inhibitors using Region-Focused CoMFA  

Balasubramanian, Pavithra K. (Department of Biomedical Sciences, College of Medicine, Chosun University)
Balupuri, Anand (Department of Biomedical Sciences, College of Medicine, Chosun University)
Cho, Seung Joo (Department of Biomedical Sciences, College of Medicine, Chosun University)
Publication Information
Journal of Integrative Natural Science / v.10, no.2, 2017 , pp. 95-104 More about this Journal
Abstract
Proviral Integration site of Moloney (Pim) murine Leukemia virus kinases is a serine/threonine specific protein kinase. It is largely involved in cell survival and proliferation. Pim-1 phosphorylates multiple cellular substrates to inhibit apoptosis and promote cell cycle progression. Over expression of Pim-1 kinase is observed in a range of malignancies and various solid cancers. High level of Pim-1 expression is seen in myeloma, acute myeloid leukemia, prostate cancer and liver carcinomas. Hence, Pim-1 is considered as an interesting cancer target. In the present study, we have performed region-focused CoMFA study on a series of imidazopyridazine derivatives as Pim-1 kinase inhibitors. A statistically acceptable region-focused CoMFA model ($q^2=0.571$; ONC=3; $r^2=0.909$) was developed. The model was then validated using Bootsrapping and progressive sampling. The contour map highlighted the regions favorable to increase the activity. Bulky substitutions in $R^2$ position of the phenyl ring could increase the activity. Similarly, small negative substitution in the $R^1$ position of the Pyridine ring could increase the activity considerably. Our results will be useful to design novel Pim-1 kinase inhibitors of this series.
Keywords
Pim-1; Region-focused CoMFA; Imidazopyridazine Derviatives; Kinase; Inhibitors;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 M. C. Nawijn, A. Alendar, and A. Berns, "For better or for worse: the role of Pim oncogenes in tumorigenesis", Nat. Rev. Cancer, Vol. 11, pp. 23-34, 2011.   DOI
2 J. D. Feldman, L. Vician, M. Crispino, G. Tocco, M. Baudry, and H. R. Herschman, "Seizure activity induces PIM-1 expression in brain", J. Neurosci. Res., Vol. 53, pp. 502-509, 1998.   DOI
3 L. Brault, C. Gasser, F. Bracher, K. Huber, S. Knapp, and J. Schwaller, "PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers", Haematologica, Vol. 95, pp. 1004-1015, 2010.   DOI
4 T. Moroy, S. Verbeek, A. Ma, P. Achacoso, A. Berns, and F. Alt, "E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice", Oncogene, Vol. 6, pp. 1941-1948, 1991.
5 H. T. Cuypers, G. Selten, A. Berns, and A. H. M. Geurts van Kessel, "Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6", Human Genetics, Vol. 72, pp. 262-265, 1986.   DOI
6 Z. P. Wang, N. Bhattacharya, M. Weaver, K. Petersen, M. Meyer, L. Gapter, and N. S. Magnuson, "Pim- 1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis", J. Vet. Sci., Vol. 2, pp. 167-179, 2001.
7 G. Selten, H. T. Cuypers, and A. Berns, "Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas", EMBO J., Vol. 4, pp. 1793-1798, 1985.
8 W. Chen, A. R. Kumar, W. A. Hudson, Q. Li, B. Wu, R. A. Staggs, E. A. Lund, T. N. Sam, and J. H. Kersey, "Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells", Cancer Cell, Vol. 13, pp. 432-440, 2008.   DOI
9 B. G. Bajaj, S. C. Verma, K. Lan, M. A. Cotter, Z. L. Woodman, and E. S. Robertson, "KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity", Virology, Vol. 351, pp. 18-28, 2006.   DOI
10 E. M. Rainio, H. Ahlfors, K. L. Carter, M. Ruuska, S. Matikainen, E. Kieff, et al., "Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity", Virology, Vol. 333, pp. 201-206, 2005.   DOI
11 L. Pasqualucci, P. Neumeister, T. Goossens, G. Nanjangud, R. S. K. Chaganti, R. Kuppers, R. Dalla-Favera, "Hypermutation of multiple proto-oncogenes in B-cell diffuse large cell lymphomas", Nature, Vol. 412, pp. 341-346, 2001.   DOI
12 S. Guo, X. Mao, J. Chen, B. Huang, C. Jin, Z. Xu, and S. Qiu, "Overexpression of Pim-1 in bladder cancer", J. Exp. Clin. Cancer Res., Vol. 29, pp. 161-167, 2010.   DOI
13 W. W. Chen, D. C. Chan, C. Donald, M. B. Lilly, and A. S. Kraft, "Pim family kinases enhance tumor growth of prostate cancer cells", Mol. Cancer Res., Vol. 3, pp. 443-451, 2005.   DOI
14 J. Kim, M. Roh, and S. A. Abdulkadir, "Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity", BMC Cancer, Vol. 10, pp. 248-262, 2010.   DOI
15 M. E. Nga, N. N. M. Swe, K. T. Chen, L. Shen, M. B. Lilly, S. P. Chan, M. Salto-Tellez, and K. Das, "PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications", Int. J. Exp. Pathol., Vol. 91, pp. 34-43, 2010.   DOI
16 P. K. Balasubramanian and S. J. Cho, "HQSAR analysis on novel series of 1-(4-phenylpiperazin-1-yl-2-(1H-Pyrazol-1-yl) ethanone derivatives targeting CCR1", J. Chosun Natural Sci., Vol. 6, pp. 163-169, 2013.   DOI
17 N. Shah, B. Pang, K. G. Yeoh, S. Thorn, C. S. Chen, M. B. Lilly, et al., "Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal", Eur. J. Cancer, Vol. 44, pp. 2144-2151, 2008.   DOI
18 M. Bachmann and T. Moroy, "The serine/threonine kinase Pim-1", Int. J. Biochem. Cell Biol., Vol. 37, pp. 726-730, 2005.   DOI
19 P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014.   DOI
20 A. Balupuri and S. J. Cho, "Exploration of the binding mode of indole derivatives as potent HIV-1 inhibitors using molecular docking simulations", J. Chosun Natural Sci., Vol. 6, pp. 138-142, 2013.   DOI
21 C. G. Gadhe and S. J. Cho, "Importance of silicon atom in the drug design process", J. Chosun Natural Sci., Vol. 5, pp. 229-232, 2012.   DOI
22 S. J. Cho, "The importance of halogen bonding: A tutorial", J. Chosun Natural Sci., Vol. 5, pp. 195-197, 2012.   DOI
23 R. P. Wurz, C. Sastri, D. C. D'Amico, B. Herberich, C. L. M. Jackson, L. H. Pettus, A. S. Tasker, B. Wu, N. Guerrero, J. R. Lipford, J. T. Winston, Y. Yang, P. Wang, Y. Nguyen, K. L. Andrews, X. Huang, M. R. Lee, C. Mohr, J. D. Zhang, D. L. Reid, Y. Xu, Y. Zhou, and H.-L. Wang, "Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors." Bioorg. Med. Chem. Lett., Vol. 26, pp. 5580-5590, 2016.   DOI
24 SYBYLx2.1, Tripos International, 1699 South Hanley Road, St. Louis, Missouri, 63144, USA.
25 P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "3D QSAR studies of Mks (TTK) kinase inhibitors based on CoMFA", Vol. 9, pp. 113-120, 2016.   DOI
26 R. D. Cramer, D. E. Patterson, and J. D. Bunce, "Comparative molecular field analysis (CoMFA). Effect of shape on binding of steroids to carrier proteins", J. Am. Chem. Soc., Vol. 110, pp. 5959-5967, 1988.   DOI
27 P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "3D QSAR study on pyrrolopyrimidines-based derivatives as LIM2 kinase inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 285-292, 2015.   DOI